bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery

Contributed by: Business Wire

Logo

Images

CRISPR-Ready ioGlutamatergic Neurons (Graphic: Business Wire)

Business Wire embedded0

Tags

Science

Stem Cells

Biotechnology

Research

Health

Medical Devices

Health Technology

Genetics

More Like This

ioMotor Neurons (Photo: Business Wire)

bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)

bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference

Scientists at King's College London and bit.bio Collaborate to Develop Multi-Cell Models of the Human Brain With Optimised Open-Source Protocols for Use by Any Researcher

bit.bio launches ioAstrocytes, advancing how scientists can model the human brain (Photo: Business Wire)

bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain

(Graphic: Business Wire)

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network

bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease

bit.bio's cell therapy pipeline November 2023 (Graphic: Business Wire)

bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy